← Human Trials & Peer-Reviewed Studies
Pretreatment with somatostatin analog SMS 201-995 potentiates growth hormone (GH) responsiveness to GH-releasing factor in short children
Plain-language guide to PMID 8257527 (1993): randomized controlled trial study of Octreotide and GHRH (Growth Hormone-Releasing Hormone) in 37 children.
Key Facts
- PMID
- 8257527
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 1993
- Study type
- Randomized Controlled Trial
- Authors
- Dickerman Z et al. (3 authors)
- DOI
- 10.1210/jcem.77.3.8257527
What This Study Did, in Plain Language
What Was Tested
Researchers studied Octreotide and GHRH (Growth Hormone-Releasing Hormone) in this randomized controlled trial publication.
In the present study, the researchers tested the hypothesis that prior administration of the long-acting somatostatin analog, SMS 201-995 (SMS), will enhance GH responsiveness to a subsequent GRF challenge.
Two study protocols were employed in 37 children with short stature [M = 31, F = 6, ages 11.8 +/- 1.6 yr (mean +/- SEM), height -2.25 +/- 0.55 SDS (SD scores)].
Who Took Part
The abstract describes 37 children taking part.
PubMed indexes the participants as children and teenagers, both men and women.
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.
What Was Measured
In the present study, the researchers tested the hypothesis that prior administration of the long-acting somatostatin analog, SMS 201-995 (SMS), will enhance GH responsiveness to a subsequent GRF challenge.
Two study protocols were employed in 37 children with short stature [M = 31, F = 6, ages 11.8 +/- 1.6 yr (mean +/- SEM), height -2.25 +/- 0.55 SDS (SD scores)].
Topics PubMed links to this paper include Arginine, Blood Glucose, Drug Synergism, Growth Disorders, Growth Hormone, Growth Hormone-Releasing Hormone and Insulin.
What This Means in Plain Language
The paper is a randomized study of Octreotide and GHRH (Growth Hormone-Releasing Hormone) in 37 children.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1993 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Octreotide compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.